-+ 0.00%
-+ 0.00%
-+ 0.00%
Yingpai Pharmaceutical-B (07630): Senapali was approved for listing by the European Commission
Share
Listen to the news

According to Zhitong Finance App, Yingpai Pharmaceutical-B (07630) announced that the innovative drug Senapali (Chinese product name: Pai Shuning®, overseas product name: Sepalna®) has officially obtained a final decision from the European Commission (EC) to approve it for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The approval was made by the European Commission (EC) based on positive opinions from the European Medicines Agency (EMA) Committee on Medicines for Human Use (CHMP). Since then, senapalil has become the first first-line maintenance PARP inhibitor for advanced ovarian cancer in China to be approved and marketed by the European Union, marking another breakthrough for domestically produced innovative drugs targeting ovarian cancer in the European market.

Sepalna® (Sepalna®) is a novel, highly active PARP1/2 inhibitor independently developed by our company. Its unique molecular structure ensures excellent target selectivity and a wide safety window. Senapalil capsules were approved by China's National Drug Administration in January 2025 to be used as first-line maintenance treatment for adult patients with advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have achieved complete or partial remission from platinum chemotherapy, and were then included in the “National Medical Insurance Drug List” in December 2025. The company is actively promoting clinical and regulatory development of senapalil around the world. At the same time, the company is also promoting the life cycle management of senapalil, exploring opportunities for combined treatment, and expanding it to multiple indications.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending